Related Experiment Videos
Actions of nisoldipine in cardiovascular disease
D J Duncker1, L J Van Woerkens, P W Serruys
1Thoraxcenter, Erasmus University Rotterdam, The Netherlands.
Insights
Nisoldipine demonstrates potent vasodilatory effects, improving cardiac output and coronary blood supply in cardiovascular patients. It shows promise in managing myocardial ischemia and heart failure, with potential antiplatelet and antiatherosclerotic benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Nisoldipine exhibits significant systemic and coronary vasodilatory properties.
- Previous studies indicate benefits in patients with cardiovascular disease.
Purpose of the Study:
- To review the cardiovascular effects of nisoldipine.
- To explore its potential in treating myocardial ischemia, heart failure, and coronary artery disease.
Main Methods:
- Review of existing studies on nisoldipine's effects.
- Analysis of its impact on cardiac output, coronary blood flow, and ischemic indicators.
Main Results:
- Nisoldipine enhances cardiac output and coronary blood supply, exceeding demand.
- It favorably affects indicators of exercise-induced myocardial ischemia.
- The drug may normalize elevated left ventricular filling pressures and improve cardiac function in heart failure patients.
- Experimental data suggests antifibrillatory activity and partial inhibition of platelet aggregation.
Conclusions:
- Nisoldipine offers therapeutic potential for cardiovascular disease, including heart failure and myocardial ischemia.
- Its vasodilatory, antiplatelet, and potential antiatherosclerotic effects warrant further clinical investigation for coronary artery disease management.
Abstract:
The potent systemic and coronary vasodilatory properties of nisoldipine have been demonstrated in several studies in patients with cardiovascular disease. The increase in cardiac output results from enhancements of both stroke volume and heart rate, while coronary blood supply increases in excess of demand. There is evidence that nisoldipine favourably affects several indicators of myocardial ischemia during exercise such as time to onset of anginal complaints and ST segment changes. Furthermore, in patients with elevated left ventricular filling pressures and reduced cardiac pump function the drug tends to normalize these parameters, thus opening new avenues for the treatment of patients with heart failure. The effect of nisoldipine on the incidence of ventricular arrhythmias has not yet been studied in patients, but experimental evidence shows an antifibrillatory activity at doses which may, however, not be clinically applicable. Finally, in healthy men, nisoldipine partially inhibits platelet aggregation. This, together with a potential antiatherosclerotic effect, could be of additional benefit to patients with coronary artery disease.